Latest news about Aarti Pharma Labs
Aarti Pharma Labs
700.75
-5.15(-0.73%)
Company Performance:
View Company Insights1D-0.73%
1M+0.43%
6M-1.07%
1Y-18.06%
5Y+143.10%
More news about Aarti Pharma Labs
04Apr 26
Aarti Pharmalabs Promoter Pledges 27.84 Lakh Shares Worth ₹177.90 Crore
Aarti Pharmalabs promoter Mr. Mirik Rajendra Gogri has pledged 27,84,094 shares representing 3.08% of the company's share capital to two financial institutions - Bajaj Financial Securities Limited and 360 One Distribution Services Limited. The pledge, created on March 25, 2026, secures a borrowing of ₹75 crore against shares valued at ₹177.90 crore, providing a security cover ratio of 2.37. The encumbered shares represent only 7% of his total promoter holding of 43.10%.
04Apr 26
Aarti Pharmalabs Promoter Pledges 15.20 Lakh Shares Under Regulation 31
Aarti Pharmalabs Limited disclosed that promoter Mr. Renil Rajendra Gogri created a pledge of 15,19,919 shares representing 1.68% of the company's share capital in favor of three financial institutions - Aditya Birla Capital Limited, Bajaj Financial Securities Limited, and 360 One Distribution Services Limited. The pledge, valued at INR 97,12,28,241, was created on March 25, 2026, for personal use and represents 3.89% of the promoter's total shareholding of 43.10% in the company.
28Mar 26
Aarti Pharmalabs Receives Single FDA Form 483 Observation for Tarapur Unit-IV Following Inspection
Aarti Pharmalabs Limited has received a single procedural Form 483 observation from the US FDA following inspection of its Tarapur Unit-IV manufacturing facility. The inspection concluded on March 27, 2026, and the company has formally notified BSE and NSE under SEBI Regulation 30, committing to submit corrective and preventive actions within the stipulated timeframe.
24Mar 26
Aarti Pharmalabs Reports Chemical Leak at Tarapur Unit Under SEBI Regulation 30
Aarti Pharmalabs Limited reported a minor chemical leak incident at its Tarapur facility under SEBI Regulation 30 compliance. The incident involved dimethyl sulphate during tanker loading operations, resulting in 22 workers being hospitalized for precautionary observation. With no casualties or property damage, normal operations resumed within 24 hours while investigation proceedings continue.
13Feb 26
Aarti Pharmalabs Limited Clarifies Delay in Regulatory Disclosure to BSE
Aarti Pharmalabs Limited has clarified to BSE the reason behind a delayed regulatory disclosure under SEBI Regulation 30. The company explained that the required 24-hour disclosure timeline was missed because the concerned official was on leave from February 3-5, 2026, and the matter came to attention only upon their return. The clarification was submitted on February 13, 2026, with the company requesting BSE to take the explanation on record and emphasizing that the delay was inadvertent.
11Feb 26
Aarti Pharmalabs Q3FY26 Results and Earnings Call Recording Now Available
Aarti Pharmalabs delivered mixed Q3FY26 results with operational revenue of INR 4,253 million, showing sequential growth but year-on-year decline. The company demonstrated strong EBITDA margin recovery to 24.22% and continues expanding its Xanthine capacity while managing operational challenges at Atali facility.
11Feb 26
Aarti Pharmalabs Issues Corrigendum to Dividend Record Date Intimation for FY26
Aarti Pharmalabs Limited filed a corrigendum on February 10, 2026, to correct a typographical error in its dividend record date intimation from the previous day. The company clarified that the dividend was declared for Financial Year 2025-26, not 2024-25 as incorrectly mentioned earlier. Company Secretary Jeevan Mondkar confirmed no other changes were made to the original filing, ensuring accurate regulatory compliance with both BSE and NSE.
09Feb 26
Aarti Pharmalabs Allots 10,457 Equity Shares Under Performance Stock Option Plan 2023
Aarti Pharmalabs Limited allotted 10,457 equity shares of Rs. 5 face value each to employees under PSOP 2023 on February 09, 2026. The allotment increased the company's paid-up equity capital to Rs. 45,32,88,755, representing 9,06,57,751 total shares. The newly issued shares rank pari-passu with existing equity shares and comply with SEBI regulations.
06Feb 26
Aarti Pharmalabs Limited Receives Rs 2.60 Lakh Penalty from CGST Authority
Aarti Pharmalabs Limited has received a Rs 2.60 lakh penalty from CGST and Central Excise authority under Section 74 of CGST Act, 2017. The penalty is part of a larger demand of Rs 31,15,608 related to alleged excess Input Tax Credit availment and incorrect tax liability declarations for FY2022-23 and FY2023-24. The company states no material impact on financials or operations is expected.
02Feb 26
Aarti Pharmalabs Limited Schedules Q3FY26 Earnings Conference Call for February 10, 2026
Aarti Pharmalabs Limited has scheduled its Q3FY26 earnings conference call for February 10, 2026 at 4:00 PM IST. The group meeting will feature Chairman Mr. Rashesh Gogri, Vice Chairperson Mrs. Hetal Gogri Gala, and CFO Mr. Piyush Lakhani discussing quarterly financial results. The company has provided domestic and international dial-in access, with toll-free numbers available for Hong Kong, Singapore, USA, and UK participants.
01Jan 26
Aarti Pharmalabs Limited Appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D
Aarti Pharmalabs Limited has appointed Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D effective January 01, 2026, following Board approval based on Nomination and Remuneration Committee recommendation. Dr. Bandichhor brings 25 years of experience in API-R&D and Process Chemistry, with strong academic credentials including M.Sc. degrees and Ph.D. in Chemistry, plus postdoctoral training from universities in Germany and USA. He was previously associated with Dr. Reddy's Laboratories in Hyderabad.
17Nov 25
Aarti Pharmalabs Reports 11% Revenue Growth in Q2FY26, Revises EBITDA Growth Guidance
Aarti Pharma Labs reported a 11% year-on-year revenue growth for Q2FY26, reaching INR 417.00 crores. However, EBITDA declined to INR 75.00 crores from INR 85.00 crores, and PAT decreased to INR 31.00 crores from INR 48.00 crores. The company's Xanthine Derivatives segment contributed 51% to turnover, API and Intermediates 39%, and CDMO-CMO Services 10%. The Atali plant was inaugurated in September, and Xanthine expansion is progressing as planned. Aarti Pharma Labs revised its FY26 EBITDA growth guidance to 8-12% year-on-year, with the CDMO-CMO business expected to exceed earlier projections.
09Nov 25
Aarti Pharmalabs Reports Strong Q2 Performance with 11% Revenue Growth
Aarti Pharma Labs announced unaudited Q2 and H1 FY2026 results. Q2 standalone revenue increased 11.2% to Rs 417.29 crore, with net profit up 45.3% to Rs 30.85 crore. H1 FY2026 revenue grew 2.8% to Rs 792.60 crore, while net profit rose 8.9% to Rs 52.08 crore year-over-year. The company operates in the pharmaceuticals segment and has global subsidiaries including Aarti USA Inc and Aarti Pharmachem Ltd. A joint venture with Ganesh Polychem Limited became effective from April 1, 2025.
09Nov 25
Aarti Pharma Labs Bolsters Leadership with Two Key Senior Management Appointments
Aarti Pharma Labs Limited has announced two significant appointments to its senior management team, effective November 10, 2025. Mr. Hemant Gundare, with a doctorate in Green Chemistry, joins as Head Corporate - EHS (Environment, Health & Safety). Mr. Shrihari S. Mane, with 32 years of experience in API manufacturing, has been appointed as Chief Technology Officer (API). These appointments, approved by the Board of Directors on November 9, 2025, aim to enhance the company's environmental sustainability, safety practices, and technological capabilities in API manufacturing.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Mankind Pharma
Zydus Life Science
Lupin
Aurobindo Pharma
Laurus Labs
1,880.30
(-0.11%)
6,893.00
(-0.27%)
4,429.20
(-0.69%)
1,399.50
(-0.73%)
1,321.90
(-1.00%)
2,583.90
(+3.66%)
1,040.85
(+2.15%)
2,285.50
(-0.08%)
1,517.50
(+0.31%)
1,361.10
(+1.20%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
